Literature DB >> 8815758

The variant forms of autoimmune hepatitis.

A J Czaja1.   

Abstract

OBJECTIVES: To review the diagnostic criteria for autoimmune hepatitis, to characterize the variant forms of autoimmune hepatitis, and to indicate appropriate therapies for this condition. DATA SOURCES: A MEDLINE search (1990 to 1995) of the English-language literature, review of a personal library of journals and reprints (1975 to 1995), and review of references selected from the bibliographies of identified articles. Terms used in the MEDLINE search included the names of all autoimmune liver diseases, viral hepatitis and autoimmunity, cryptogenic hepatitis, and overlap syndromes. STUDY SELECTION: All articles that discussed atypical clinical features, mixed diagnostic findings, and variations in treatment response were selected. DATA EXTRACTION: Data were selected from 548 articles. DATA SYNTHESIS: Standardized criteria permit the confident diagnosis of autoimmune hepatitis, but they exclude many patients who have features suggesting autoimmunity. Such patients have findings indicative of both autoimmune hepatitis and another disorder (overlap syndromes) or findings that are inconsistent with the classic definition of autoimmune hepatitis (outlier syndromes). Overlap syndromes include combinations of autoimmune hepatitis and primary biliary cirrhosis, primary sclerosing cholangitis, or chronic viral hepatitis. Treatment of these syndromes requires identification of the predominant disorder and selection of the most appropriate drug regimen. Outlier syndromes include autoimmune cholangitis and cryptogenic chronic hepatitis. Corticosteroids or ursodeoxycholic acid are treatment options for patients with autoimmune cholangitis; corticosteroids can also benefit patients with cryptogenic chronic hepatitis. Grading each clinical feature and developing a composite score can permit comparison of the variants and a determination of the similarity between the variants and autoimmune hepatitis.
CONCLUSIONS: Variant forms of autoimmune hepatitis are common. Recognition of them is important in assessing common pathogenic mechanisms, developing effective treatment strategies, and refining classification schemes.

Entities:  

Mesh:

Year:  1996        PMID: 8815758     DOI: 10.7326/0003-4819-125-7-199610010-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  38 in total

Review 1.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

Review 2.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 3.  Variant forms of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

4.  A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome.

Authors:  Rabin Rahmani; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-04

5.  A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome.

Authors:  Ashaur Azhar; Mumtaz A Niazi; Kashif Tufail; Ashraf H Malek; Manjula Balasubramanian; Victor Araya
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-04

6.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

7.  Vaccination-induced autoimmune hepatitis.

Authors:  Ganesh R Veerappan; Brian P Mulhall; Kent C Holtzmuller
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

8.  Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model.

Authors:  Mikio Zeniya; Fumitoki Watanabe; Toshio Morizane; Minoru Shibata; Shiro Maeyama; Masayoshi Kage; Yasuni Nakanuma; Gotaro Toda
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

9.  Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status.

Authors:  P Invernizzi; P M Battezzati; A Crosignani; P Zermiani; M Bignotto; N Del Papa; M Zuin; M Podda
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

Review 10.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.